6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
elsewhere O
in O
labeling O
: O
* O
Cardiovascular B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Malignant B-OSE_Labeled_AE
Neoplasms I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
> O
= O
5 O
percent O
) O
are O
: O
abdominal O
pain O
, O
asthenia O
, O
pain O
, O
back O
pain O
, O
headache O
, O
flatulence O
, O
nausea O
, O
depression O
, O
insomnia O
, O
breast O
pain O
, O
endometrial O
hyperplasia O
, O
leucorrhea O
, O
vaginal O
hemorrhage O
, O
and O
vaginitis O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Pfizer O
Inc O
. O
at O
1-800-438-1985 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Study O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

During O
the O
first O
year O
of O
a O
2-year O
clinical O
trial O
with O
2,333 O
postmenopausal B-Not_AE_Candidate
women O
with O
a O
uterus O
between O
40 O
and O
65 O
years O
of O
age O
( O
88 O
percent O
Caucasian O
) O
, O
1,012 O
women O
were O
treated O
with O
conjugated O
estrogens O
, O
and O
332 O
were O
treated O
with O
placebo O
. O

Table O
1 O
summarizes O
treatment-related O
adverse O
reactions O
that O
occurred O
at O
a O
rate O
of O
> O
= O
1 O
percent O
in O
any O
treatment O
group O
. O

Table O
1 O
: O
TREATMENT O
RELATED O
ADVERSE O
REACTIONS O
AT O
A O
FREQUENCY O
> O
= O
1 O
PERCENT O
PREMARIN0.625 O
mg O
( O
n=348 O
) O
PREMARIN0.45 O
mg O
( O
n=338 O
) O
PREMARIN0.3 O
mg O
( O
n=326 O
) O
Placebo O
( O
n=332 O
) O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
38 O
( O
11 O
) O
28 O
( O
8 O
) O
30 O
( O
9 O
) O
21 O
( O
6 O
) O
Asthenia B-OSE_Labeled_AE
16 O
( O
5 O
) O
8 O
( O
2 O
) O
14 O
( O
4 O
) O
3 O
( O
1 O
) O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
18 O
( O
5 O
) O
11 O
( O
3 O
) O
13 O
( O
4 O
) O
4 O
( O
1 O
) O
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
2 O
( O
1 O
) O
3 O
( O
1 O
) O
4 O
( O
1 O
) O
2 O
( O
1 O
) O
Generalized B-NonOSE_AE
edema I-NonOSE_AE
7 O
( O
2 O
) O
6 O
( O
2 O
) O
4 O
( O
1 O
) O
8 O
( O
2 O
) O
Headache B-OSE_Labeled_AE
45 O
( O
13 O
) O
47 O
( O
14 O
) O
44 O
( O
13 O
) O
46 O
( O
14 O
) O
Moniliasis B-OSE_Labeled_AE
5 O
( O
1 O
) O
4 O
( O
1 O
) O
4 O
( O
1 O
) O
1 O
( O
0 O
) O
Pain B-OSE_Labeled_AE
17 O
( O
5 O
) O
10 O
( O
3 O
) O
12 O
( O
4 O
) O
14 O
( O
4 O
) O
Pelvic B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
10 O
( O
3 O
) O
9 O
( O
3 O
) O
8 O
( O
2 O
) O
4 O
( O
1 O
) O
Cardiovascular B-NonOSE_AE
system I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
4 O
( O
1 O
) O
4 O
( O
1 O
) O
7 O
( O
2 O
) O
5 O
( O
2 O
) O
Migraine B-OSE_Labeled_AE
7 O
( O
2 O
) O
1 O
( O
0 O
) O
0 O
3 O
( O
1 O
) O
Palpitation B-NonOSE_AE
3 O
( O
1 O
) O
3 O
( O
1 O
) O
3 O
( O
1 O
) O
4 O
( O
1 O
) O
Vasodilatation B-NonOSE_AE
2 O
( O
1 O
) O
2 O
( O
1 O
) O
3 O
( O
1 O
) O
5 O
( O
2 O
) O
Digestive B-NonOSE_AE
system I-NonOSE_AE
Constipation B-OSE_Labeled_AE
7 O
( O
2 O
) O
6 O
( O
2 O
) O
4 O
( O
1 O
) O
3 O
( O
1 O
) O
Diarrhea B-NonOSE_AE
4 O
( O
1 O
) O
5 O
( O
1 O
) O
5 O
( O
2 O
) O
8 O
( O
2 O
) O
Dyspepsia B-NonOSE_AE
7 O
( O
2 O
) O
5 O
( O
1 O
) O
6 O
( O
2 O
) O
14 O
( O
4 O
) O
Eructation B-OSE_Labeled_AE
1 O
( O
0 O
) O
1 O
( O
0 O
) O
4 O
( O
1 O
) O
1 O
( O
0 O
) O
Flatulence B-OSE_Labeled_AE
22 O
( O
6 O
) O
18 O
( O
5 O
) O
13 O
( O
4 O
) O
8 O
( O
2 O
) O
Increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
4 O
( O
1 O
) O
1 O
( O
0 O
) O
1 O
( O
0 O
) O
2 O
( O
1 O
) O
Nausea B-NonOSE_AE
16 O
( O
5 O
) O
10 O
( O
3 O
) O
15 O
( O
5 O
) O
16 O
( O
5 O
) O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
nutritional I-NonOSE_AE
Hyperlipidemia B-OSE_Labeled_AE
2 O
( O
1 O
) O
4 O
( O
1 O
) O
3 O
( O
1 O
) O
2 O
( O
1 O
) O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
5 O
( O
1 O
) O
2 O
( O
1 O
) O
4 O
( O
1 O
) O
3 O
( O
1 O
) O
Weight B-NonOSE_AE
gain I-NonOSE_AE
11 O
( O
3 O
) O
10 O
( O
3 O
) O
8 O
( O
2 O
) O
14 O
( O
4 O
) O
Musculoskeletal B-NonOSE_AE
system I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
6 O
( O
2 O
) O
3 O
( O
1 O
) O
2 O
( O
1 O
) O
5 O
( O
2 O
) O
Leg B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
10 O
( O
3 O
) O
5 O
( O
1 O
) O
9 O
( O
3 O
) O
4 O
( O
1 O
) O
Myalgia B-OSE_Labeled_AE
2 O
( O
1 O
) O
1 O
( O
0 O
) O
4 O
( O
1 O
) O
1 O
( O
0 O
) O
Nervous B-NonOSE_AE
system I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
6 O
( O
2 O
) O
4 O
( O
1 O
) O
2 O
( O
1 O
) O
4 O
( O
1 O
) O
Depression B-NonOSE_AE
17 O
( O
5 O
) O
15 O
( O
4 O
) O
10 O
( O
3 O
) O
17 O
( O
5 O
) O
Dizziness B-OSE_Labeled_AE
9 O
( O
3 O
) O
7 O
( O
2 O
) O
4 O
( O
1 O
) O
5 O
( O
2 O
) O
Emotional B-NonOSE_AE
lability I-NonOSE_AE
3 O
( O
1 O
) O
4 O
( O
1 O
) O
5 O
( O
2 O
) O
8 O
( O
2 O
) O
Hypertonia B-OSE_Labeled_AE
1 O
( O
0 O
) O
1 O
( O
0 O
) O
5 O
( O
2 O
) O
3 O
( O
1 O
) O
Insomnia B-OSE_Labeled_AE
16 O
( O
5 O
) O
10 O
( O
3 O
) O
13 O
( O
4 O
) O
14 O
( O
4 O
) O
Nervousness B-OSE_Labeled_AE
9 O
( O
3 O
) O
12 O
( O
4 O
) O
2 O
( O
1 O
) O
6 O
( O
2 O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
appendages I-NonOSE_AE
Acne B-OSE_Labeled_AE
3 O
( O
1 O
) O
1 O
( O
0 O
) O
8 O
( O
2 O
) O
3 O
( O
1 O
) O
Alopecia B-OSE_Labeled_AE
6 O
( O
2 O
) O
6 O
( O
2 O
) O
5 O
( O
2 O
) O
2 O
( O
1 O
) O
Hirsutism B-OSE_Labeled_AE
4 O
( O
1 O
) O
2 O
( O
1 O
) O
1 O
( O
0 O
) O
0 O
Pruritus B-OSE_Labeled_AE
11 O
( O
3 O
) O
11 O
( O
3 O
) O
10 O
( O
3 O
) O
3 O
( O
1 O
) O
Rash B-OSE_Labeled_AE
6 O
( O
2 O
) O
3 O
( O
1 O
) O
1 O
( O
0 O
) O
2 O
( O
1 O
) O
Skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
4 O
( O
1 O
) O
2 O
( O
1 O
) O
0 O
1 O
( O
0 O
) O
Sweating B-NonOSE_AE
4 O
( O
1 O
) O
1 O
( O
0 O
) O
3 O
( O
1 O
) O
4 O
( O
1 O
) O
Urogenital B-NonOSE_AE
system I-NonOSE_AE
Breast B-NonOSE_AE
disorder I-NonOSE_AE
6 O
( O
2 O
) O
3 O
( O
1 O
) O
3 O
( O
1 O
) O
6 O
( O
2 O
) O
Breast B-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
3 O
( O
1 O
) O
4 O
( O
1 O
) O
7 O
( O
2 O
) O
3 O
( O
1 O
) O
Breast B-NonOSE_AE
neoplasm I-NonOSE_AE
4 O
( O
1 O
) O
4 O
( O
1 O
) O
7 O
( O
2 O
) O
7 O
( O
2 O
) O
Breast B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
37 O
( O
11 O
) O
39 O
( O
12 O
) O
24 O
( O
7 O
) O
26 O
( O
8 O
) O
Cervix B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
8 O
( O
2 O
) O
4 O
( O
1 O
) O
5 O
( O
2 O
) O
0 O
Dysmenorrhea B-OSE_Labeled_AE
12 O
( O
3 O
) O
10 O
( O
3 O
) O
4 O
( O
1 O
) O
2 O
( O
1 O
) O
Endometrial B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
4 O
( O
1 O
) O
2 O
( O
1 O
) O
2 O
( O
1 O
) O
0 O
Endometrial B-OSE_Labeled_AE
hyperplasia I-OSE_Labeled_AE
16 O
( O
5 O
) O
8 O
( O
2 O
) O
1 O
( O
0 O
) O
0 O
Leukorrhea B-OSE_Labeled_AE
17 O
( O
5 O
) O
17 O
( O
5 O
) O
12 O
( O
4 O
) O
6 O
( O
2 O
) O
Metrorrhagia B-OSE_Labeled_AE
11 O
( O
3 O
) O
4 O
( O
1 O
) O
3 O
( O
1 O
) O
1 O
( O
0 O
) O
Urinary B-NonOSE_AE
tract I-NonOSE_AE
infection I-NonOSE_AE
1 O
( O
0 O
) O
2 O
( O
1 O
) O
1 O
( O
0 O
) O
4 O
( O
1 O
) O
Uterine B-OSE_Labeled_AE
fibroids I-OSE_Labeled_AE
enlarged I-OSE_Labeled_AE
6 O
( O
2 O
) O
1 O
( O
0 O
) O
2 O
( O
1 O
) O
2 O
( O
1 O
) O
Uterine B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
11 O
( O
3 O
) O
5 O
( O
1 O
) O
3 O
( O
1 O
) O
2 O
( O
1 O
) O
Vaginal B-NonOSE_AE
dryness I-NonOSE_AE
1 O
( O
0 O
) O
2 O
( O
1 O
) O
1 O
( O
0 O
) O
6 O
( O
2 O
) O
Vaginal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
46 O
( O
13 O
) O
13 O
( O
4 O
) O
6 O
( O
2 O
) O
0 O
Vaginal B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
14 O
( O
4 O
) O
10 O
( O
3 O
) O
12 O
( O
4 O
) O
5 O
( O
2 O
) O
Vaginitis B-OSE_Labeled_AE
18 O
( O
5 O
) O
7 O
( O
2 O
) O
9 O
( O
3 O
) O
1 O
( O
0 O
) O
6.2 O
Postmarketing O
Experience O
The O
following O
additional O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
PREMARIN O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
possible O
always O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Genitourinary B-NonOSE_AE
system I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
uterine I-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
; O
dysmenorrheal B-OSE_Labeled_AE
or O
pelvic O
pain I-OSE_Labeled_AE
, O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
size I-OSE_Labeled_AE
of I-OSE_Labeled_AE
uterine I-OSE_Labeled_AE
leiomyomata I-OSE_Labeled_AE
, O
vaginitis B-OSE_Labeled_AE
, O
including O
vaginal B-OSE_Labeled_AE
candidiasis I-OSE_Labeled_AE
, O
change B-OSE_Labeled_AE
in I-OSE_Labeled_AE
cervical I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
, O
ovarian B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
endometrial B-OSE_Labeled_AE
hyperplasia I-OSE_Labeled_AE
, O
endometrial B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
leukorrhea B-OSE_Labeled_AE
. O

Breasts B-OSE_Labeled_AE
Tendern I-OSE_Labeled_AE
ess O
, O
enlargement O
, O
pain O
, O
discharge O
, O
galactorrhea B-OSE_Labeled_AE
, O
fibrocystic B-OSE_Labeled_AE
breast I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
gynecomastia B-OSE_Labeled_AE
in O
males O
. O

Cardiovascular B-NonOSE_AE
Deep B-OSE_Labeled_AE
and O
superficial O
venous I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
thrombophlebitis B-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
stroke B-OSE_Labeled_AE
, O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
. O

Gastrointestinal B-NonOSE_AE
Nausea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
bloating B-OSE_Labeled_AE
, O
cholestatic B-OSE_Labeled_AE
jaundice I-OSE_Labeled_AE
, O
increased O
incidence O
of O
gallbladder B-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
enlargement B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hepatic I-OSE_Labeled_AE
hemangiomas I-OSE_Labeled_AE
, O
ischemic B-OSE_Labeled_AE
colitis I-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
Chloasma B-OSE_Labeled_AE
or O
melasma B-OSE_Labeled_AE
that O
may O
persist O
when O
drug O
is O
discontinued O
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
nodosum I-OSE_Labeled_AE
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
scalp I-OSE_Labeled_AE
hair I-OSE_Labeled_AE
, O
hirsutism B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
. O

Eyes B-NonOSE_AE
Retinal B-OSE_Labeled_AE
vascular I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
intolerance B-OSE_Labeled_AE
to I-OSE_Labeled_AE
contact I-OSE_Labeled_AE
lenses I-OSE_Labeled_AE
. O

Central B-NonOSE_AE
nervous I-NonOSE_AE
system I-NonOSE_AE
Headache B-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
mental B-OSE_Labeled_AE
depression I-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
mood B-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
epilepsy I-OSE_Labeled_AE
, O
dementia B-OSE_Labeled_AE
, O
possible O
growth B-OSE_Labeled_AE
potentiation I-OSE_Labeled_AE
of I-OSE_Labeled_AE
benign I-OSE_Labeled_AE
meningioma I-OSE_Labeled_AE
. O

Miscellaneous O
Increase B-OSE_Labeled_AE
or O
decrease O
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
, O
glucose B-OSE_Labeled_AE
intolerance I-OSE_Labeled_AE
, O
aggravation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
porphyria I-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
arthralgias B-OSE_Labeled_AE
, O
leg B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
, O
changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
libido I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
asthma I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
triglycerides I-OSE_Labeled_AE
, O
hypersensitivity B-OSE_Labeled_AE
. O

